Litcius/Paper detail

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, Elena Élez, Takayuki Yoshino, Alberto Sobrero, James C. Yao, Pilar García‐Alfonso, Judit Kocsis, Antonio Cubillo Gracián, Andrea Sartore‐Bianchi, Taroh Satoh, Violaine Randrian, Jiří Tomášek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S. Höchster, John C. Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng

2023The Lancet323 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRegorafenibInternal medicineClinical endpointColorectal cancerPlaceboPhases of clinical researchOncologyCancerSurgeryChemotherapyClinical trialPathologyAlternative medicineColorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGastric Cancer Management and Outcomes